Wiley Rein Files Amicus Brief in Mylan, Inc. v. Daiichi Sankyo Co.
Yesterday, Wiley Rein filed an amicus brief with the U.S. Supreme Court on behalf of the Generic Pharmaceutical Association (GPhA) in support of a petition for certiorari in patent dispute case Mylan, Inc. v. Daiichi Sankyo Co. The brief asks for the Court's clarification of its definition for "obviousness," a criticallyimportant issue when determining the validity of a patent.
Wiley Rein lawyers James H. Wallace, John B. Wyss, Helgi C. Walker and Thomas R. McCarthy wrote the amicus brief on behalf of GPhA and argue that allowing for patents on "obvious" advancements in pharmaceutical drugs results in significantly delaying the entry of generic drugs, thereby causing serious harm to American taxpayers and the federal government, the largest buyer of pharmaceuticals.
The use of generics prescriptions saves the national health care system more than $1 billion dollars every three days. But when generic drugs are improperly barred from the market, Wiley Rein attorneys argue, prescription drug prices soar. As a result, individual consumers not only suffer serious financial harm, but the high prices for brand-name prescription drugs often cause the sick and elderly to skip needed doses or to forgo taking expensive prescription drugs altogether.
A decision by the Supreme Court on certiorari is expected in March.
Senior Communications Manager